Based on the analysis of Bradford's law for 3,000 related to the IPC classification technology, 18 core patented technologies in Chinese medicine field have been determined from1988 to 2009. In view of distribution regulation of corporate patent intensity, the core patented technology in our country has advantage and with a patent-density core between 11.38 and 7.83 as the first step of Beijing, Tianjin, Shandong, Guizhou and Jiangxi. Then, the second step is followed by the central and southwest China, including Sichuan, Zhejiang, Jiangsu and Shanghai, including 11 provinces, autonomous regions and municipalities, with the corporate patent density between 4.56 and 3.76. Furthermore, the third step is also followed by the northwest, northeast and southeast regions including Shanxi, Tibet, Xinjiang, Ningxia and Qinghai with the core density between 3.72 and 1.53. Although the second, third classification are less at enterprise patent density, the characteristics can not be replaced.